Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ritlecitinib in nonsegmental vitiligo
CTR20230893Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ritlecitinib tosilate in nonsegmental vitiligo, sponsored by Pfizer. Started Jun 2023; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on CTR20230893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230893.